
News|Articles|June 17, 2025
Pharmacy Practice in Focus: Oncology
- June 2025
- Volume 7
- Issue 4
Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD
Fact checked by: Luke Halpern, Associate Editor
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Advertisement
Advertisement
A group of experts will present an encore abstract titled "Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using Real-World Data" at the 2025 Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20. The abstract was originally shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Related to this article

A transplant pharmacist looks at what azacitidine plus venetoclax’s event-free survival advantage over intensive chemotherapy means for induction selection, and why it doesn’t yet replace 7+3 or CPX-351.

In the phase 3 REGAL trial, galinpepimut-S reached a median overall survival of 24.0 months, compared with 14.7 months for best available treatment, in patients in second or later remission.

Vorasidenib analyses featured at SNO 2026 examine longer-term outcomes and seizure burden in IDH-mutant glioma, underscoring the importance of sustained monitoring during oral therapy.

Extended INDIGO and FIREFLY-1 results presented at SNO 2026 put seizure burden during vorasidenib therapy and time off tovorafenib in pediatric low-grade glioma into focus.

An analysis of 40 economic studies found PCV20 and PCV21 outperformed older strategies, while low uptake and racial gaps limited the benefit of vaccination.

Early germline BRCA testing identifies patients with metastatic pancreatic adenocarcinoma who can be considered for olaparib maintenance if their disease has not progressed after at least 16 weeks of first-line platinum chemotherapy.

A new US consensus on pancreatic enzyme replacement therapy in pancreatic cancer highlights how pharmacists can counsel patients on taking enzymes with food, check response early, and address barriers to filling the prescription.
Advertisement
Advertisement
